Larimar Therapeutics (LRMR) Cash from Investing Activities (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Cash from Investing Activities for 13 consecutive years, with $18.8 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Cash from Investing Activities rose 129.68% year-over-year to $18.8 million; the trailing twelve-month figure through Jun 2025 stood at $79.8 million (up 144.09% YoY), and the FY2025 full-year result was $100.3 million, up 217.48% from the prior year.
• Cash from Investing Activities advanced to $18.8 million in Q2 2025 per LRMR's latest filing, from $14.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $92.2 million in Q1 2023 and bottomed at -$68.4 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$3.1 million across 5 years, with a median of $1.3 million in 2021.
• The sharpest annual moves came in 2021 and 2024: Cash from Investing Activities plunged 84787.5% in 2021, then soared 830.2% in 2024.
• Over 5 years, Cash from Investing Activities stood at $6.5 million in 2021, then slumped by 904.84% to -$52.2 million in 2022, then soared by 94.97% to -$2.6 million in 2023, then jumped by 830.2% to $19.2 million in 2024, then declined by 1.85% to $18.8 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $18.8 million, $14.4 million, and $19.2 million for Q2 2025, Q1 2025, and Q4 2024 respectively.